Skip to content

Released Nov 4, 2026, after the close

10-Q filed Nov 5, 2026, 36 days after period end · 0001653477-26-000064

Q3 2026 · 10-Q
Revenue$305.10M−8.4% vs Q3 2025−2.9% vs Q2 2026
Net Income$49.30M+13.3% vs Q3 2025+39.7% vs Q2 2026
EPS Diluted$1.41+19.5% vs Q3 2025+41.0% vs Q2 2026
Gross Profit$132,800,000−0.8%
Operating Cash Flowderived$99,200,000−23.5%
Free Cash Flowderived$85,500,000−27.4%
Margins · derived
Gross margin43.5%+3.3 pt vs Q3 2025
Net margin16.2%+3.1 pt vs Q3 2025

What the release said

Ingevity reports third quarter 2026 financial results Third Quarter 2026 Results and Recent Highlights:

Adjusted EBITDA from continuing operations was $108.0 million, and Ingevity narrowed its full-year 2026 adjusted EBITDA outlook to $385 million to $395 million, maintaining the midpoint of the prior range.23

Third quarter free cash flow was $85.5 million, and share repurchases totaled approximately $39 million at a weighted average price of $71.45 per share.45

The company continues to advance the sale of Advanced Polymer Technologies, and the timing of an announced agreement may extend into early 2027.6

Net sales
$305.1 million7
Net income from continuing operations
$51.1 million8
Diluted EPS from continuing operations
$1.46 per diluted share8
Adjusted diluted EPS from continuing operations
$1.639
Adjusted EBITDA from continuing operations
$108.0 million2
Full year 2026 adjusted EBITDA outlook
$385 million to $395 million Narrowed range for full year 2026, midpoint of prior range maintained3
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$305.10M$333.10M$333.80M$446.00M
Net Income$49.30M$43.50M-$107.20M$25.20M
EPS Diluted$1.41$1.18-$2.94$0.69

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Ingevity Corp · CIK 1653477 · Engraved from SEC EDGAR